Key Highlights

  • Distribution Agreement: China Resources Pharmaceutical Commercial Group Medical Devices will serve as exclusive distributor for Baird Medical's MWA products in 19 markets in the People's Republic of China.
  • Initial Purchase Order: The agreement was accompanied by an initial order of approximately RMB 6 million, equivalent to roughly $900,000.
  • Geographic Focus: The 19 markets targeted are regions where Baird Medical has historically had limited direct commercial presence.
  • US Expansion Context: Baird Medical has been building out its US commercial infrastructure since late 2025, with products adopted at institutions including Mayo Clinic and Columbia University Medical Center.

Baird Medical Investment Holdings Limited(NASDAQ:BDMD), the global medical device company specializing in microwave ablation technology, has entered into a distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd., a Subsidiary of the Hong Kong-listed China Resources Pharmaceutical Group. Under the deal, China Resources Medical Devices becomes the exclusive distributor for Baird's specified MWA products across 19 markets in the People's Republic of China, with an initial purchase order totaling approximately RMB 6 million.

The Agreement and Its Strategic Rationale

The Partnership expands Baird Medical's coverage in a home market where it has built an established Leadership position but has historically relied on direct sales infrastructure. The 19 markets included in the agreement represent regions where Baird's direct commercial presence has been limited, suggesting the intent is geographic expansion rather than replacement of existing channels. China Resources Medical Devices brings a nationwide distribution network and relationships across hospitals and healthcare systems in the targeted regions.

Haimei Wu, Chairwoman and CEO of Baird Medical, described the agreement as a validation of the company's MWA technology by one of the leading medical technology distributors in the country. She also framed the partnership as complementary to the company's ongoing US expansion, indicating that Baird Medical is pursuing multiple markets simultaneously rather than sequencing them.

Microwave Ablation and Its Growing Applications

Microwave ablation is a minimally invasive procedure that uses focused microwave energy to destroy tissue, including solid tumors, without requiring open surgery. Baird Medical's MWA system is FDA-cleared for soft tissue ablation and is being introduced to US clinical practice primarily for the treatment of benign thyroid nodules, where it offers an alternative to conventional surgery. The technology also has potential applications in other solid tumor types, and the company has been developing additional products including an IRE-based (irreversible electroporation) system and an AI-powered robotic ablation platform.

In the US, Baird Medical's MWA products have been adopted at a growing number of academic and private practice settings, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company began accelerating its US commercial build-out in late 2025, making the China and US expansion efforts essentially concurrent.

Risks

Exclusive distribution agreements create dependency on the performance and priorities of the distribution partner. If China Resources Medical Devices does not allocate sufficient sales resources to Baird's products, or if its priorities shift toward other product lines, Baird Medical would have limited recourse while the exclusive arrangement is in place. The agreement's financial terms beyond the initial purchase order — including minimum purchase commitments, contract duration, and renewal conditions — are not disclosed in the public announcement, which makes it difficult to assess how material the Revenue contribution is expected to be. The company also operates across multiple geographies including Argentina, Vietnam, Indonesia, and Pakistan, adding operational complexity to its growth strategy.

What to Watch Next

The size and pace of follow-on orders from China Resources Medical Devices beyond the initial RMB 6 million purchase will indicate whether the distribution arrangement is translating into meaningful commercial activity in the targeted regions. Concurrently, how quickly Baird Medical's US Business scales from the institutional adoptions already announced will determine whether the company is tracking toward meaningful commercial-stage revenue in its second major market.

Sector Context

The market for minimally invasive ablation technologies has been expanding as both payers and patients increasingly prefer procedures that avoid open surgery, reduce recovery times, and can often be performed in outpatient settings. In China, where a large and aging population drives significant Demand for oncology and thyroid disease management, microwave ablation has seen adoption at major hospitals faster than in some Western markets, partly because regulatory pathways for the technology were established earlier. Baird Medical's established position in China gives it credibility when entering new regional markets through distribution partners like China Resources.